BUY Emcure Pharmaceuticals Limited — Swati Hotkar, Nirmal Bang Securities
bySwati Hotkar, Nirmal Bang SecuritiesHorizon: 1–3 months2 Jun 2026via NDTV Profit (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
3 advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · adjacent horizon·28 Aug · 5d ago
Emcure Pharma receives USFDA EIR for Sanand facility; regulator classifies it as 'VAI'; here's what it means
NewsCnbc-Tv18·8 Aug · 4w ago
Emcure Pharmaceuticals Q1 Results: Net profit rises 42%, international business aids topline growth
NewsCnbc-Tv18·6 Aug · 4w ago
Emcure Pharma Q1: Net Profit Jumps 42%; CEO Satish Mehta Appointed As Chairman
NewsNdtv-Profit·6 Aug · 4w ago
1 other SEBI-registered advisor has an active short-term BUY call on this stock
Advisor consensus · same horizon·8 Jul · 2mo ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.